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Background: The social and medical impact of rare diseases is increasingly recognized. Amyotrophic lateral
sclerosis (ALS) is the most prevalent of the motor neuron diseases. It is characterized by rapidly progressive damage
to the motor neurons with a survival of 2–5 years for the majority of patients. The objective of this work is to
describe the study protocol and the implementation steps of the amyotrophic lateral sclerosis (ALS) registry Swabia,
located in the South of Germany.
Methods/Design: The ALS registry Swabia started in October 2010 with both, the retrospective (01.10.2008-
30.09.2010) and prospective (from 01.10.2010) collection of ALS cases, in a target population of 8.6 million persons
in Southern Germany. In addition, a population based case–control study was implemented based on the registry
that also included the collection of various biological materials.
Retrospectively, 420 patients (222 men and 198 women) were identified. Prospectively data of ALS patients were
collected, of which about 70% agreed to participate in the population-based case–control study. All participants in
the case–control study provided also a blood sample. The prospective part of the study is ongoing.
Discussion: The ALS registry Swabia has been implemented successfully. In rare diseases such as ALS, the
collaboration of registries, the comparison with external samples and biorepositories will facilitate to identify risk
factors and to further explore the potential underlying pathophysiological mechanisms.
Keywords: Amyotrophic lateral sclerosis, Registry, Risk factorsBackground
A registry is an organized system that collects clinical
and other data to a given purpose with methods of ob-
servational studies in a standardized manner [1]. Basic-
ally, it composites data concerning all cases of a
particular disease or all subjects sharing specified
characteristics. Ideally it is implemented in a defined
population and may also include longitudinal informa-
tion. The systematic collection of data allows evaluating* Correspondence: gabriele.nagel@uni-ulm.de
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reproduction in any medium, provided the orspecific outcomes, health-related characteristics and end
points according to epidemiological criteria [1].
Different registries with a focus on disease, treatment,
special patient or vulnerable groups (such as pregnant
women) or outcome exist: procedure-related registries
(centered on specific drugs, therapeutic, or diagnostic
procedures), patient registries, or specific disease regis-
tries. Depending on the focus of the registry, the target
population, data collection and methods will be chosen
accordingly [2]. The selection of the target population
depends also on the research question, which can be
related to the epidemiology of the disease, course of dis-
ease and mortality, (adverse) effects of treatment ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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variety of medical registries exist [3,4].
During the past years, it is increasingly recognized that
rare diseases are an important medical and public health
issue [5]. Amyotrophic lateral sclerosis (ALS), the most
frequent of the motor neuron diseases (MND), is such a
rare disease with an estimated incidence of 2–3 cases
per 100,000 person-years [6,7]. The majority of patients
die within 3 to 5 years, mostly as a result of respiratory
failure. The disease leads to a rapidly progressive damage
of the motor neurons with subsequent muscle paralysis.
ALS starts in 40-50% of patients in the upper extrem-
ities, usually initially with progressive atrophy and par-
alysis of the small hand muscles [6,7]. About 20-30% of
patients show symptoms of the lower limbs at first signs
of manifestation, increasing the risk for stumbling and
as a consequence the risk for consecutive falls [6,7].
The diagnosis ALS relies on clinical criteria such as
progressive paralysis, amyotrophy, hyperreflexia, and
spasticity [8,9]. During the course of disease, dysphagia,
dyspnea, depression, pain and sleep disorders can occur
[6]. The treatment of ALS is based on symptomatic and
pathogenetic orientated therapy. Although the combin-
ation of both approaches has led to a significantly better
survival of ALS patients [6,9], the prognosis is yet poor.
There is evidence that smoking and physical activity is
associated with ALS risk [6,10]. However, the etiology
and pathogenesis of ALS is still largely unknown and its
genetic component is only partially understood. Major
gaps remain in the understanding of its pathogenesis
with the basic principle of selective vulnerability and po-
tentially resulting therapeutic consequences.
With this paper, we would like to describe the study
protocol and the implementation steps of the amyo-
trophic lateral sclerosis (ALS) registry Swabia and the
adjunct population-based case–control study. We also
illustrate the potential of disease registries as efficient
epidemiological approach for interdisciplinary and ana-
lytical research of rare diseases by combining the clinical
registry data with information from an epidemiological
population-based case–control study.
Methods
Mission of the ALS registry Swabia
The objectives of the population-based ALS registry
Swabia is to determine the incidence, prevalence and
mortality of ALS in a defined geographical region in the
South of Germany. Furthermore, by means of a
population-based case–control study, potential risk
factors such as life time history of physical activity,
sports, head injuries, and metabolic factors will be fur-
ther investigated to name only a few risk factors which
are in the focus. In addition, the collection of blood
samples and other biological materials shall be used toanalyze genetic and biological factors to elucidate the
underlying pathophysiological mechanisms and to iden-
tify potential starting points for the development of new
treatment approaches.
Study design and study population
The ALS registry Swabia is conducted as a clinical-
epidemiological registry with the aim to collect data on
all newly diagnosed ALS cases in the target population
to estimate epidemiological data on incidence, patient and
disease characteristics, and natural history of ALS. In
addition, a case–control study is attached to investigate
risk factors of ALS and factors of disease progression in
an analytical setting. The study population consists of all
inhabitants living in the area of Swabia as from the year
2008. The study region is defined by cities and counties
that reflect the geographical or administrative borders of
Swabia, located in the South of Germany (Figure 1).
Registry cases
The inclusion and exclusion criteria for the ALS registry
are clearly defined by the diagnosis of ALS, the date of
diagnosis and the residence at the time of diagnosis.
ALS cases are defined by the El Escorial criteria. De-
pending on the onset of symptoms, following locational
criteria can be distinguished: bulbar, cervical, thoracic,
and lumbosacral and signs of upper or lower motor
neurons. To confirm the diagnosis of ALS, the informa-
tion is verified by neurologists using the internationally
standardized "El Escorial criteria" [11,12]. Patients with
suspected ALS are tracked and evaluated during the
clinical course.
The regional cooperation partners identify patients
and obtain informed consent, before they notify the ALS
registry at the Ulm University. In the ALS registry, both
case report forms (CRFs, Table 1) and electronic notes
per Email or Fax are used. Information on the onset of
ALS, the localization, diagnostic and treatment procedures
are collected by study nurses from the medical records.
ALS is a clinically based diagnosis. In order to achieve
standardization, all cases are reviewed by an experienced
neurologist according to the El Escorial criteria [11,19].
Regular biannual meetings and special diagnostic
courses are organized with all cooperation partners to
strengthen the regional network and to ensure a high
compliance with the standardized data collection
procedures. An ALS registry homepage has been set
up to inform about the purpose of the ALS registry
Swabia, the data collection procedures and results of
the registry [20].
Study design
The ALS registry comprises data for the descriptive
analyses of onset and the natural history of ALS
Figure 1 Study region of the ALS-registry Swabia located in the South of Germany.
Nagel et al. BMC Neurology 2013, 13:22 Page 3 of 10
http://www.biomedcentral.com/1471-2377/13/22progression. The ALS registry functions as an observa-
tional study conducted as a population-based cohort
study with a retrospective and a prospective part. The
implementation of the ALS registry in Swabia started 1st
of October 2010 with prospective collection of all newly
diagnosed ALS cases in the target population. Inaddition, information on ALS cases diagnosed between
01.10.2008 until 30.09.2010 has been collected retro-
spectively (Figure 2). The retrospective branch has the
aim to implement the registry infrastructure and man-
agement in the target area and to provide first estimates
of the incidence in the study region. Regional
Table 1 Information collected and instruments used in ALS registry Swabia
ALS-case report form Items Source
Symptoms
Upper, lower extremities (distal, prox.), bulbar, spastic,
cerebellar and further symptoms
According to EURALS
Localization
HSP, PLS, PMA, SMA, Bulbar, Bulbarparalysis, Flail- Arm-
Syndrome, Flail- Leg-Syndrome
According to EURALS
Diagnosis Date, proof According to EURALS
Treatment Past, current According to EURALS
Case-Control questionnaire
Sociodemographic status Age, gender, school education, occupation According to EURALS
Care / care givers
Family history
Motor neuron diseases in first and second degree
relatives
Comorbidities
List of common chronic diseases and other diseases
(history)
Medication Life-time history of anti-inflammatory drugs
Smoking Life-time history According to EURALS
Alcohol consumption Life-time history According to EURALS
Diet Diet and nutritional supplements
Physical activity Life-time history of sports and physical activities According to EURALS
Trauma Life-time history According to EURALS
Injuries Life-time history According to EURALS
Reproductive history (for women)
Menstruation, hormons, pregnancy, menopause,
operations
According to EURALS
Quality of life SF 12
M. Morfeld, I. Kirchberger, M.
Bullinger [13]
Subjective quality of life SQoL J. Bernheim (1999) [14]
Neuropsychiatric tests (Hospital Anxiety and
Depression Scale)
HADS
C. Herrmann-Lingen, U. Buss, R. P.
Snaith (1995) [15]
Bedside test to assess the function of the frontal brain
(Frontal Assessment Battery)
FAB Dubois et al. [16]
Montreal Cognitive Assessment MoCA Nasreddine et al. [17]
Coping Achievement Motivation Scale AMS J. W. B. Lang, S. Fries (2006) [18]
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consent to send the information to the ALS registry at
the Neurological University Hospital Ulm. To date 36
regional partners collaborate in the registry (see list at
the end of the publication).
Patients from the prospective registry part diagnosed
after 01.10.2010 were also asked to provide informed
consent to participate in a population-based case–
control study in order to investigate risk factors of
ALS. Control subjects are selected in the region by a
random sample of the corresponding registration
office, contacted and invited to participate in the
case–control study. To each case, two sex and age
frequency-matched controls are randomly sampled
from the general population on the relevant catch-
ment area of the case. The potential controls are
invited to participate by mail and in case of participa-
tion informed consent is obtained.Data collection and quality assurance
ALS registry
The data collection office of the ALS registry Swabia is
located in the Department of Neurology at the Ulm Uni-
versity to which new cases are reported, checked eligibil-
ity for inclusion and were the encryption of personal
data is performed. The data coordinating and analysis
center is located at the Institute of Epidemiology and
Medical Biometry where only pseudomyzed data of the
cases are stored. The identification and recruitment of
the age, gender and region matched controls is also
organized from here. Internal quality checks and ana-
lyses are also performed on a routine basis in the data
coordinating and analysis center.
Case–control study
Patients and controls who provided their informed con-
sent to participate in the case–control study will be visited
Figure 2 Recruitment procedures and collected information in the ALS registry Swabia and the attached case-control study.
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and blood sampling. The instruments and tests are identi-
cally conducted in both groups (Table 1) and have been
adapted to the instruments used by the European ALS
group EURALS [21].
Biological samples
Blood sample (EDTA-plasma, serum, PAXgene) are
collected from cases and controls in a standardized man-
ner. EDTA-plasma and serum are obtained by centrifu-
gation for 10 min at 2000 × g and 4°C. PAXgene
samples were processed within the same day according
to the standard protocol. Blood specimens were trans-
ferred into 0.5-1.0 ml sample containers with screw tops
and were stored for analysis of biomarkers of exposure
and susceptibility. ALS patients are asked to allocate dis-
pensable material from routine examinations such as
cerebral spinal fluid and muscle biopsies for the biobank
which is associated with the ALS registry. Blood samples
and specimens were stored for future analysis of
biomarkers of exposure and genetic analyses in -80° Cel-
sius freezers or in liquid nitrogen.
Follow-up
For all cases of the case–control study active follow-up
is conducted one year after inclusion into the study.
Data on the course of disease and quality of life is
collected by a standardized questionnaire. A study nurse
visits the patients to perform neuropsychological testsand to collect a blood sample. Instruments used in the
follow-up are based on the baseline examination and
include questions on respiratory aids and parenteral nu-
trition (Table 1). Information of the vital status of
participants will be collected from all participants. If a
patient deceased the respective death certificate will be
collected from the regional public health office. In
Germany, the location of death and not the location of
the last place of residence is determining in which local
health office the death certificate is stored. The main
cause of death will be coded according to the coding
rules of the German mortality statistics. In addition, in-
formation on comorbid conditions will be collected.Statistical methods and analysis plans
The size of the target population has been estimated by
power calculation for the registry-based case–control
study. Under the assumption of an ALS incidence of 2
to 3 cases per 100,000 person-years, we estimated that a
target population of about 8.6 million inhabitants will be
sufficient to collect data from 200–240 patients per year
[21].
For the associated case–control study, we estimated
that about 75% of patients will participate. Under the
assumptions of a significance level of two-sided α = 0.05,
power calculation revealed that the power of the study
will be large enough for major exposure variables to de-
tect an association of an odds ratio of two or larger with
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cases and 630 control cases).
Descriptive epidemiological measures, such as preva-
lence and incidence of ALS, will be estimated from the
ALS registry data (Table 2). These measures will also be
estimated for small geographic areas to investigate po-
tential differences. Comparison with data collected in
the EURALS project [22] will be performed in combin-
ation with internal, external or historical comparisonTable 2 Objectives and epidemiological measures
obtained from the clinical ALS-registry and additional
information derived from the attached case–control
study




-Symptoms at disease manifestation
-Distribution of localization at onset
-Time from first symptoms to clinical diagnosis
(diagnostic delay)
-Distribution of diagnostic procedures in routine
clinical care of ALS
-Application of therapeutic means and measures
during follow-up
-Background rate of adverse events in ALS
population
-Rate and risk factors of comorbid diseases in ALS
population
-Natural history of disease (progression free survival,




-(Long-term) efficacy of therapies under routine
clinical care conditions on various outcomes
(progression free survival, overall survival) and
occurrence of adverse events (safety outcomes)
-Identification of prognostic markers of disease
progression (includes assessment of potential new
drug targets
b. Epidemiological ALS Registry (includes geographical analyses)
Descriptive
measures:
-All of the above mentioned (see 2.a), additionally
plus incidence
plus mortality







-in nested case – control study





plus investigation of pathogenetic pathways
(blood samples)groups. Standardized rates and relative risks can be
calculated. Besides descriptive epidemiological measures,
explorative analyses and the testing of hypothesis can be
performed. Table 2 shows the objectives and epidemio-
logical measures obtained from the clinical ALS registry
and additional information derived from the attached
case–control study.
In the year 2013, according to the power analysis the
number in the case–control study will be sufficiently
large to start the analyses on potential risk factors. Previ-
ously we will evaluate the completeness of the ALS-
registry Swabia by calculation of the ALS incidence in
Swabia, comparison with other data sources and apply-
ing spatial scan statistics. For known exposure factors in
the target population, relative and attributable risks can
be calculated. Additional clinical data during follow-up
will facilitate to describe the course of disease and the
outcome of the disease during the clinical course of dif-
ferent phenotypes and to determine the survival time.
Ethical considerations
Data protection is a prerequisite of a registry, which
includes transparency of the data collection and ana-
lyses. Informed consent is necessary for the collection of
personal data. Withdrawal of the data should be possible
at any time. International, national and state rules have
been considered implementing the ALS registry Swabia.
Approvals of the ethical committees of the Ulm Univer-
sity, medical association (Landesärztekammer) of the
state of “Baden-Württemberg”, and the medical associ-
ation of the state of “Bayern” have been obtained.
In the target region, 36 neurological departments and
clinics are cooperating to notify newly diagnosed ALS
cases to the ALS registry Swabia. In addition, five adja-
cent neurological centers, not directly located in the
study region, but potentially receiving cases for diagno-
sis, care and treatment of the study region are visited an-
nually in order to identify all patients from the target
population. Therefore a complete coverage of all medical
centers specialized in the diagnosis and treatments of
ALS are included.
Implementation
Regional cooperation partners report new cases to the
data collection office at the Neurological Clinic, where
tests for duplicates and the encryption of personal data
are performed. So far, with the exception of two admin-
istrative regions, reporting of cases works very well. The
infrastructure and the processes for the registry and
case–control study have been implemented. Initially we
informed the public, the scientific community and
physicians in the region about the ALS registry in
Swabia. Before starting with the implementation of the
ALS-registry, a pilot study among 10 patients was
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organization of the ALS registry Swabia. Based on the
helpful experiences made in the pilot study, the
organization and the instruments were modified accord-
ingly. Standard operation procedures were written and
distributed among the study staff. The study team has
been trained concerning the general study procedures
and specific tests such as neuropsychiatric tests in order
to work according to principles of good scientific and
epidemiological practice.
The definitions of core data concerning ALS diagnosis
and phenotype, which have to be collected in all clinics
and of non-core data, have been defined in order to
guarantee the statistical analyses. Variables for the core
data are: sex, age, diagnosis, date of first symptoms and
diagnosis, date of death and cause of death. Besides
these variables, the type and the unit should be defined
for the collection of the data (e.g. for length: numerical
in m or cm). These recommendations are documented
in a standard operation handbook. In the ALS registry
Swabia, regular checks of the core data set and the end-
point data have been implemented to sustain high qual-
ity data over the entire observation period.
Baseline study characteristics
ALS registry Between October 2008 and end of
September 2010, 420 incident ALS cases were identified
(as is July 31, 2012). There were 53% men and 47%
women among ALS cases.
Prospective data Since 1st of October 2010, 188 cases
were included into the registry for the case–control part
of the study, 61% were men and 39% women. The first
follow-up includes a self-administered standardized
questionnaire, a personal interview including several
neuro-psychological logical tests, and the collection of a
blood sample. The prospective part of the ALS registry
including case–control study and the collection of
biomaterial is ongoing.
ALS case – control study In the case–control study,
124 ALS patients agreed to participate and provided
informed consent. According to the place of residence,
age and gender of the patients, a random sample in the
registration office is requested. The potential control
persons are contacted and invited to participate in the
study. After agreement, the study material is sent and a
date for the visit of the study nurse is fixed. On average
10 randomly selected control subjects were selected,
then contacted and the first 2 participating control
subjects included. So far, data from 175 control persons
have been collected. Notably, it is much more difficult to
recruit healthy controls for the study and certainincentives should be included into the recruitment
process to give patients and additional motivation. Most
are not aware of their importance to help to combat this
terrible disease. So far, comparison of the age and sex
distributions in the case–control study with the retro-
spective and prospective ALS registry data revealed no
indication of selection bias.
Discussion
In this paper, we describe the rational, the study design
and the basic characteristics of the ALS registry Swabia
and the adjunct population-based ALS case–control
study. We further discuss the prerequisites and the
potentials of registries in the investigation of rare
diseases. The epidemiological ALS registry Swabia has
been successfully implemented in the target region
covering about 8.6 million inhabitants. Retrospectively
420 incident ALS cases were identified, of whom 53%
were men and 47% women. Since October 2010 data of
188 ALS cases have been collected prospectively.
Epidemiological registries record all newly diagnosed
cases of illnesses in a geographically defined area. The
main criterion for the inclusion in an epidemiological
registry is the residence at diagnosis. For the ALS regis-
try a core data set has been defined. As part of the data
collection process has to be included in the routine clin-
ical work of the collaborators and cannot be reimbursed
in the framework of the current registry, the collection
of a relatively small number of well-defined variables will
be more cost-effective and will increase compliance and
completeness. In addition, immediate data quality assur-
ance procedures have to be implemented to guarantee
the quality of data in a database [23]. Especially
procedures concerning the data transfer from patient’s
record to the data extraction sheet are especially vulner-
able, and 100% source monitoring as done as routine
practice in many clinical trials, is not affordable in regis-
tries. Prompt data collection close to the clinical
procedures results in higher data quality [1] and makes
necessary inquiries also more successful.
For the informative value of epidemiological registries,
completeness is required for external (as well as internal)
validity and generalizability to similar populations [1].
To achieve completeness in the ALS registry Swabia data
is collected from different sources in the catchment area
and also from adjuncts regions. However, the specific
clinical features and severe progression of ALS makes it
very possible that all patients are treated in a specialized
neurological clinics or ambulances which then include
the patients in this registry. Newly diagnosed ALS cases
are recruited based on strict inclusion criteria and notifi-
cation rules in order to collect the relevant information
in the target populations with minimal work-load. All
cases are reviewed by a study neurologist. Clear
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management and regular outputs with feed-back to co-
operation partners as well as incentives contribute to
maintain compliance and high recruitment rates. The
financial reimbursement for external collaboration
partners is determined according to a fair market pricing
value that considers the time necessary to include the
patients into the registry and the time they need to pro-
vide data usually already available as they are collected
during standard routine clinical care practice. No add-
itional procedures or measurements are in general
requested and therefore the reimbursement scheme is so
much lower compared to a clinical trial.
In addition, the comparison with external data
resources, such as the mortality registry, provides infor-
mation on the completeness of registries. The aggregated
data on ALS mortality in the State of Baden-
Württemberg were used for checks of completeness
[24]. In the ALS registry Swabia, causes of death are
identified by active follow-up. In Europe the age-
adjusted incidence rate of ALS was 2.16 per 100.000
person-years [25]. The data from population registries
allow identifying the number of new cases and
monitoring trends in incidence over a longer period.
Registries collect clinical and other information with
means of observational studies, while analytical studies
using registry data may, depending on the research ques-
tion, open new possibilities of knowledge gain in the
context of clinical registries and be conducted as cohort,
case- cohort or case–control study [1]. Cohort studies
are the classical method of investigating the causes of
disease of frequent and common diseases (e.g. myocar-
dial infarction or diabetes). When the prevalence is low
or even rare, case–control studies are more suitable.
This study type also allows the investigation of many po-
tential risk factors including biological markers to fur-
ther investigate the potential etiology and biological
pathways involved. For specific research questions, more
refined study designs can be applied. Nevertheless the
choice of a control group is complex, because registry-
based analytical studies need to control for confounders.
Design strategies include matching according to specific
case-characteristics for example sex, age and study re-
gion. In the ALS study Swabia, we ensured also simul-
taneous data collection for cases and controls. In
addition, the analysis strategy has to be based on a
multivariable analysis which an a priori strategy how to
identify potential confounding factors and how to select
and include them into a multivariable model [26].
For rare diseases such as ALS, registries are an ap-
proach to collect systematically data in a sufficiently
large population. Sample size calculations and oversam-
pling are methodological considerations, by which we
try to achieve valid registry data. Standardization of allprocesses, regular quality checks and continuous
training of the staff is required to ensure high quality.
For the ALS registry Swabia, a standard operation hand-
book has been written and is used to minimize system-
atic errors, both in the data collection phase as well as
in data management and analysis including program-
ming errors, unclear definitions of variables or violation
of the data collection protocol [23]. In addition, regular
communication and publication of the data can reinforce
the credibility of the registry data and increase the par-
ticipation. In the ALS registry Swabia, this has been
achieved by setting up an ALS-registry home-page and
providing the clinicians with relevant published informa-
tion [27].
The pooling of registry data will increase the power to
investigate prognostic factors. In the ALS registry Swabia,
we adapted the instruments to the ones applied in the
EURALS consortium. Registry data can be used to re-
cruit patients in a case–control study in order to investi-
gate risk factors in population with heterogeneous risk
[21]. The linkage to a biorepository provides additional
research opportunities linking experimental with popu-
lation research in order to develop diagnostic and thera-
peutic approaches [28,29].
Registries are an increasingly applied, powerful instru-
ment in medical research in particular for rare diseases.
The implementation of a medical registry is a long-term
investigation, which requires careful considerations
whether the methodological and budgetary aspects meet
the purpose of the projected registry. They are a rela-
tively cost-effective method to collect health informa-
tion, which is usually already locally available, but time
and effort should not be underestimated that is neces-
sary to collect high quality data. However, in particular
for the investigation of rare diseases, the implementation
of registries including biological markers seems to be a
promising approach to better understand the natural
history of rare diseases, a better understanding of disease
pathways, which then may be used as new target for
treatment [21,30].
When in Ulm the decision for a registry was made, all
contributors were made aware that the value and success
of the registry is directly related to the quality of each
component of information coming from participating
health care professionals.
Summary and conclusions
The ALS registry Swabia has been successfully
implemented with excellent support of a large number
of collaborating partners. In the future, the combination
of a clinical registry in a defined region with a
population-based control arm, allows the next gener-
ation of descriptive, epidemiological indicators, and the
exploration of possible risk factors and pathophysiology
Nagel et al. BMC Neurology 2013, 13:22 Page 9 of 10
http://www.biomedcentral.com/1471-2377/13/22(in particular of rare diseases). Registries collecting high
quality information can strengthen the interdisciplinary
research and present an interactive platform between
patients, clinicians and scientists. However, certain
methodological aspects and quality characteristics need
to be taken into account to ensure the carrying capacity
of the data.
Abbreviations
ALS: Amyotrophic lateral sclerosis; EURALS: European studies on amyotrophic
lateral sclerosis; HSP: Hereditary Spastic Paraplegia; MND: Motorneuron
disease; PLS: Primary lateral sclerosis; PMA: Progressive Muscular Atrophy;
SMA: Spinal Muscular Atrophy; SF 12: Short Form 12 Health Survey;
SQoL: Subjective quality of life; HADS: Hospital Anxiety and Depression scale;
FAB: Frontal Assessment Battery; MoCA: Montreal Cognitive Assessment;
AMS: Achievement Motives Scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GN, ACL, DR were involved in the study conception and design. ACL and GN
were involved in financial support. Study material or patients was provided
by the members of ‘The ALS Registry Study Group’ *. Data were collected
and assembled by GN, HU and AR. All authors were involved in the data
analysis and interpretation. GN, HU and DR were writing the manuscript,
which was finally approved by all authors. All authors read and approved the
final manuscript.
Acknowledgements
ALS Registry Study Group
G. Arnold, Klinikum Sindelfingen-Böblingen, Abteilung Neurologie
T. Adam, Praxis EMSA Singen
H. Bäzner, Bürgerhospital Stuttgart, Abteilung Neurologie
H. Baier, ZFP Südwürttemberg, Abteilung Epileptologie, Weissenau
J. Beattie, Ostalb-Klinikum Aalen, Neurologische Klinik
F. Behne, ZFP Südwürttemberg, Abteilung Epileptologie, Weissenau
D. Bengel, Oberschwabenklinik GmbH Ravensburg, Abteilung Neurologie
M. Bluthardt, Abteilung Neurologie, Ludwigsburg
A. Börtlein, Bürgerhospital Stuttgart, Abteilung Neurologie
C. Dettmers, Schmieder Kliniken Konstanz
B. Eppinger, Klinikum am Gesundbrunnen, Abteilung Neurologie, Heilbronn
H.-J. Gold, Klinikum am Gesundbrunnen, Abteilung Neurologie, Heilbronn
M. Hecht, Bezirkskrankenhaus Kaufbeuren, Abteilung Neurologie
B. Heimbach, University of Freiburg, Abteilung Neurologie
C. Hendrich, Klinikum Friedrichshafen, Abteilung Neurologie
B. Herting, Diakonie-Klinikum Schwäbisch Hall, Abteilung Neurologie
R. Huber, Klinikum Friedrichshafen, Abteilung Neurologie
P.-J. Hülser, Fachklinik Wangen
S. Kaendler, Kliniken Landkreis Heidenheim gGmbH, Abteilung Neurologie
A. Kaspar, Oberschwabenklinik GmbH Ravensburg, Abteilung Neurologie
H. Kimmig, Kliniken Schwenningen
C. Klötzsch, Schmieder Kliniken Allensbach, Bodensee Klinikum Hegau
J. Kühne, Schmieder Kliniken Allensbach, Bodensee Klinikum Hegau
D. Lewis, Marienhospital Stuttgart, Abteilung Neurologie
C. Lichy, Klinikum Memmingen, Abteilung Neurologie
A. Lindner, Marienhospital Stuttgart, Abteilung Neurologie
S. Lorenzl, LMU München, Abteilung Neurologie
S. Lutz-Schuhbauer, Abteilung Neurologie, Dietenbronn
M. Mäurer, Caritas Krankenhaus, Bad Mergentheim
H. M. Meinck, University of Heidelberg, Abteilung Neurologie
O. Meudt, Klinikum Memmingen
J. Müller vom Hagen, Universitätsklinikum Tübingen, Neurologische Uni-Klinik
A. Nägele, Christophsbad Göppingen, Neurologische Klinik
M. Naumann, Klinikum Augsburg, Abteilung Neurologie und
Neurophysiologie
K.-D. Neher, Vinzenz von Paul Hospital, Rottweil
O. Neuhaus, Kliniken Landkreis Sigmaringen GmbH, Abteilung Neurologie
C. Neusch, Praxis EMSA SingenL. Niehaus, Abteilung Neurologie, Winnenden
M. Patzner, Fachklinik Wangen
J. Peters, Ostalb-Klinikum Aalen, Neurologische Klinik
Y. Poerschke, Bundeswehrkrankenhaus Ulm, Abteilung Neurologie
J. Raape, ZFP Südwürttemberg, Neurologie Weissenau
P. Ratzka, Klinikum Augsburg, Abteilung Neurologie und Neurophysiologie
A. Reeh, Kliniken Landkreis Heidenheim gGmbH, Abteilung Neurologie
C. Rettenmayr, Klinikum Esslingen
J. Rothmeier, ZFP Südwürttemberg, Neurologie Weissenau
M. Sabolek, Abteilung Neurologie, Dietenbronn
M. Schabet, Abteilung Neurologie, Ludwigsburg
M. Schäff-Vogelsang, Diakonie-Klinikum Schwäbisch Hall, Abteilung
Neurologie
L. Schöls, Universitätsklinikum Tübingen, Neurologische UNI-Klinik
B. Schweigert, Caritas Krankenhaus, Bad Mergentheim
N. Sommer, Christophsbad Göppingen, Neurologische Klinik
W. Sperber, Klinikum Esslingen
M. Stroick, Klinikum Memmingen
T. Trottenberg, Abteilung Neurologie, Winnenden
F. Weber, Bundeswehrkrankenhaus Ulm, Abteilung Neurologie
C. Wessig, University of Würzburg, Abteilung Neurologie
H.-G. Will, Kliniken Schwenningen
A. Winkler, TU München, Abteilung Neurologie
Funding
This work was supported by the Deutsche Forschungsgemeinschaft (main
number 577 631, project LU 336/15-1).
Author details
1Institute of Epidemiology and Medical Biometry, Ulm University,
Helmholtzstr. 22, Ulm 89081, Germany. 2Department of Neurology, Ulm
University, Ulm, Germany.
Received: 2 October 2012 Accepted: 6 February 2013
Published: 17 February 2013
References
1. Gliklich RE, Dreyer N: Registries for Evaluating Patient Outcomes: A User’s
Guide [Internet].; 2010. [cited 2011 May 24]. Available from: http://www.ncbi.
nlm.nih.gov/books/NBK49444/.
2. Weddell JM: Registers and registries: a review. Int J Epidemiol 1973,
2(3):221–228.
3. Drolet BC, Johnson KB: Categorizing the world of registries. J Biomed
Inform 2008, 41(6):1009–1020.
4. Mathis-Edenhofer S, Piso B: Types of medical registries - definitions,
methodological aspects and quality of the scientific work with registries.
Wien Med Wochenschr 2011, 161(23–24):580–590.
5. Schieppati A, Henter J-I, Daina E, Aperia A: Why rare diseases are an
important medical and social issue. Lancet 2008, 371(9629):2039–2041.
6. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al:
Amyotrophic lateral sclerosis. Lancet 2011, 377(9769):942–955.
7. Gastl R, Ludolph AC: Amyotrophic lateral sclerosis. Nervenarzt 2007,
78(12):1449–1457. quiz 1458–1459.
8. Lulé D, Häcker S, Ludolph A, Birbaumer N, Kübler A: Depression and quality
of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int
2008, 105(23):397–403.
9. Ludolph AC: Motor neuron disease: urgently needed-biomarkers for
amyotrophic lateral sclerosis. Nat Rev Neurol 2011, 7(1):13–14.
10. Gallo V, Bueno-De-Mesquita HB, Vermeulen R, Andersen PM, Kyrozis A,
Linseisen J, et al: Smoking and risk for amyotrophic lateral sclerosis:
analysis of the EPIC cohort. Ann Neurol 2009, 65(4):378–385.
11. Brooks BR: El Escorial World Federation of Neurology criteria for the
diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor
Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation
of Neurology Research Group on Neuromuscular Diseases and the El
Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop
contributors. J Neurol Sci 1994, 124(Suppl):96–107.
12. Brooks BR: Versailles minimal dataset for diagnosis of ALS: a distillate of
the 2nd Consensus Conference on accelerating the diagnosis of ALS.
Versailles 2nd Consensus Conference participants. Amyotroph Lateral Scler
Other Motor Neuron Disord 2000, 1(Suppl 1):S79–S81.
Nagel et al. BMC Neurology 2013, 13:22 Page 10 of 10
http://www.biomedcentral.com/1471-2377/13/2213. Morfeld M, Bullinger M, Nantke J, Brähler E: The version 2.0 of the SF-36
health survey: results of a population-representative study. Soz
Praventivmed 2005, 50(5):292–300.
14. Bernheim JL: How to get serious answers to the serious question: “How
have you been?”: subjective quality of life (QOL) as an individual
experiential emergent construct. Bioethics 1999, 13(3–4):272–287.
15. Herrmann C, Buss U, und Snaith RP: HADS-D - Hospital Anxiety and
Depression Scale - Deutsche Version: Ein Fragebogen zur Erfassung von Angst
und Depressivität in der somatischen Medizin. Bern: Huber; 1995.
16. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment
Battery at bedside. Neurology 2000, 55(11):1621–1626.
17. Nasreddine ZS, Phillips N, Chertkow H: Normative data for the Montreal
Cognitive Assessment (MoCA) in a population-based sample. Neurology
2012, 78(10):765–766. author reply 766.
18. Lang JWB, Fries S: A revised 10-item version of the achievement motives
scale: psychometric properties in German-speaking samples. Eur J Psychol
Assess 2006, 22:216–224.
19. Brooks BR, Miller RG, Swash M, Munsat TL: El Escorial revisited: revised
criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph
Lateral Scler Other Motor Neuron Disord 2000, 1(5):293–299.
20. The ALS registry Swabia; 2012. www.als-register.net.
21. Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, et al:
The epidemiology of ALS and the role of population-based registries.
Biochim Biophys Acta 2006, 1762(11–12):1150–1157.
22. The European ALS Consortium (EURALS)-exercise study; 2012. http://www.
mnd.ie/current-research/eurals-exercise-study.
23. Arts DGT, De Keizer NF, Scheffer G-J: Defining and improving data quality
in medical registries: a literature review, case study, and generic
framework. J Am Med Inform Assoc 2002, 9(6):600–611.
24. State of Baden-Württemberg statistical office; 2012. http://www.statistik.
baden-wuerttemberg.de/BevoelkGebiet/.
25. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al:
Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg
Psychiatr 2010, 81(4):385–390.
26. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. Thirdth edition.
Philadelphia: Lippincott Williams and Wilkins; 2008.
27. Nagel G, Rosenbohm A, Ünal H, Rothenbacher D, Ludolph A: für die ALS-
Register-Studiengruppe. Möglichkeiten register-basierter Studien zur
Erforschung seltener Erkrankungen. Aktuelle Neurologie 2012,
39(01):12–17.
28. Heemstra HE, Van Weely S, Büller HA, Leufkens HGM, De Vrueh RLA:
Translation of rare disease research into orphan drug development:
disease matters. Drug Discov Today 2009, 14(23–24):1166–1173.
29. Rubinstein YR, Groft SC, Bartek R, Brown K, Christensen RA, Collier E, et al:
Creating a global rare disease patient registry linked to a rare diseases
biorepository database: rare disease-HUB (RD-HUB). Contemp Clin Trials
2010, 31(5):394–404.
30. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC: The case for a global rare-
diseases registry. Lancet 2011, 377(9771):1057–1059.
doi:10.1186/1471-2377-13-22
Cite this article as: Nagel et al.: Implementation of a population-based
epidemiological rare disease registry: study protocol of the amyotrophic
lateral sclerosis
(ALS) - registry Swabia. BMC Neurology 2013 13:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
